申请人:Medivation Technologies, Inc.
公开号:US08338447B2
公开(公告)日:2012-12-25
This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds of formula (I)
are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。 描述了公式(I)的化合物,以及包含该化合物的制药组合物和使用该化合物在各种治疗应用中的方法,包括治疗认知障碍,精神障碍,神经递质介导的障碍和/或神经元障碍。